Literature DB >> 22370816

Changes in the serum level of hepatitis B virus (HBV) surface antigen over the natural course of HBV infection.

Akihiro Matsumoto1, Eiji Tanaka, Susumu Morita, Kaname Yoshizawa, Takeji Umemura, Satoru Joshita.   

Abstract

BACKGROUND: Despite its status as a potential biomarker of hepatitis B virus (HBV) response to interferon treatment, the changes in hepatitis B surface antigen (HBsAg) levels over the natural course of HBV carriers have not been analyzed sufficiently.
METHODS: A total of 101 HBV carriers were followed prospectively from 1999 to 2009. HBsAg level was measured yearly during the followed period.
RESULTS: HBsAg levels at baseline ranged from -1.4 to 5.32 log IU/ml, with a median value of 3.2 log IU/ml. Lower HBsAg levels were significantly associated with higher age and lower HBV replication status. The rate of change of HBsAg levels showed two peaks, with a cut-off value of -0.4 log IU/year. Based on this, patients were tentatively classified into rapid decrease (rate of change <-0.4 log IU/year) and non-rapid decrease groups. All baseline levels of HBsAg, HB core-related Ag, and HBV DNA were lower in the rapid decrease group than in the non-rapid decrease group. Patients with persistently positive HBeAg were all classified into the non-rapid decrease group. In patients with persistently negative HBeAg, HBV DNA levels were significantly (P = 0.028) lower in the rapid decrease group than in the non-rapid decrease group.
CONCLUSIONS: Lower baseline HBsAg levels were significantly associated with older age and lower viral activity. Both a loss of HBeAg detection as well as inactive replication of HBV are suggested to be fundamental factors contributing to a rapid decrease in HBsAg over the natural course of HBV infection.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22370816     DOI: 10.1007/s00535-012-0559-2

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  21 in total

1.  Chronic hepatitis B.

Authors:  Anna S F Lok; Brian J McMahon
Journal:  Hepatology       Date:  2007-02       Impact factor: 17.425

2.  HBsAg seroclearance: the more and earlier, the better.

Authors:  Tai-Chung Tseng; Jia-Horng Kao
Journal:  Gastroenterology       Date:  2009-03-18       Impact factor: 22.682

Review 3.  Hepatitis B virus infection.

Authors:  W M Lee
Journal:  N Engl J Med       Date:  1997-12-11       Impact factor: 91.245

4.  Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B.

Authors:  Akihiro Matsumoto; Eiji Tanaka; Yoshiyuki Suzuki; Mariko Kobayashi; Yasuhito Tanaka; Noboru Shinkai; Shuhei Hige; Hiroshi Yatsuhashi; Shinya Nagaoka; Kazuaki Chayama; Masataka Tsuge; Osamu Yokosuka; Fumio Imazeki; Shuhei Nishiguchi; Masaki Saito; Kei Fujiwara; Nobuyuki Torii; Naoki Hiramatsu; Yoshiyasu Karino; Hiromitsu Kumada
Journal:  Hepatol Res       Date:  2011-11-22       Impact factor: 4.288

5.  HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy.

Authors:  Tetsuya Hosaka; Fumitaka Suzuki; Masahiro Kobayashi; Miharu Hirakawa; Yusuke Kawamura; Hiromi Yatsuji; Hitomi Sezaki; Norio Akuta; Yoshiyuki Suzuki; Satoshi Saitoh; Yasuji Arase; Kenji Ikeda; Mariko Kobayashi; Hiromitsu Kumada
Journal:  Liver Int       Date:  2010-09-14       Impact factor: 5.828

Review 6.  Management of hepatitis B: summary of a clinical research workshop.

Authors:  Jay H Hoofnagle; Edward Doo; T Jake Liang; Russell Fleischer; Anna S F Lok
Journal:  Hepatology       Date:  2007-04       Impact factor: 17.425

7.  Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients.

Authors:  Fumitaka Suzuki; Hideo Miyakoshi; Mariko Kobayashi; Hiromitsu Kumada
Journal:  J Med Virol       Date:  2009-01       Impact factor: 2.327

8.  Low serum level of hepatitis B core-related antigen indicates unlikely reactivation of hepatitis after cessation of lamivudine therapy.

Authors:  Akihiro Matsumoto; Eiji Tanaka; Masahito Minami; Takeshi Okanoue; Hiroshi Yatsuhashi; Shinya Nagaoka; Fumitaka Suzuki; Mariko Kobayashi; Kazuaki Chayama; Michio Imamura; Hiroshi Yotsuyanagi; Shigeru Nakaoka; Noboru Maki; Sumio Kawata; Hiromitsu Kumada; Shiro Iino; Kendo Kiyosawa
Journal:  Hepatol Res       Date:  2007-08       Impact factor: 4.288

9.  Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients.

Authors:  Rami Moucari; Vincent Mackiewicz; Olivier Lada; Marie-Pierre Ripault; Corinne Castelnau; Michelle Martinot-Peignoux; Agnes Dauvergne; Tarik Asselah; Nathalie Boyer; Pierre Bedossa; Dominique Valla; Michel Vidaud; Marie-Hélène Nicolas-Chanoine; Patrick Marcellin
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

10.  HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma.

Authors:  Man-Fung Yuen; Danny Ka-Ho Wong; James Fung; Philip Ip; David But; Ivan Hung; Kevin Lau; John Chi-Hang Yuen; Ching-Lung Lai
Journal:  Gastroenterology       Date:  2008-07-16       Impact factor: 22.682

View more
  2 in total

1.  Mutations of pre-core and basal core promoter before and after hepatitis B e antigen seroconversion.

Authors:  Nozomi Kamijo; Akihiro Matsumoto; Takeji Umemura; Soichiro Shibata; Yuki Ichikawa; Takefumi Kimura; Michiharu Komatsu; Eiji Tanaka
Journal:  World J Gastroenterol       Date:  2015-01-14       Impact factor: 5.742

2.  The correlation between serum HBsAg levels and viral loads depends upon wild-type and mutated HBV sequences rather than the HBeAg/anti-HBe status.

Authors:  Mo-Han Liu; Qin-Yan Chen; Tim J Harrison; Guo-Jian Li; Hai Li; Xue-Yan Wang; Yu Ju; Jin-Ye Yang; Zhong-Liao Fang
Journal:  J Med Virol       Date:  2015-04-16       Impact factor: 2.327

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.